ALNEV.PA down 99.6% to €0.0072 on EURONEXT: check cash and trial risks
ALNEV.PA stock fell 99.60% to €0.0072 on EURONEXT at market close on 14 Jan 2026, making it one of today’s top losers. Trading volume surged to 4,152,238 shares, more than double the average of 1,597,803, as investors reacted to extremely thin market capitalisation and long-dated clinical risk. The move follows no actionable earnings update since 2019, leaving fundamentals and cash runway as the primary drivers of price action.
ALNEV.PA stock: intraday move and market context
Neovacs S.A. (ALNEV.PA) closed at €0.0072 on EURONEXT with a 1-day change of -99.60% and a day range of €0.0066–€0.0076. Volume of 4,152,238 shows heavy selling pressure versus the 50-day average volume of 1,597,803.
The European healthcare sector gained modestly today while Neovacs underperformed the biotech group, highlighting stock-specific risk rather than sector weakness.
Financials and valuation for ALNEV.PA stock
Market capitalisation is listed at €3,432.00 with 476,625 shares outstanding, reflecting extreme dilution or reporting quirks in the quoted data. Trailing EPS is -221.36 and traditional P/E is not meaningful.
Key ratios show a low current ratio of 0.63 and cash per share of €2.50 (TTM metrics). Price-to-book and price-to-sales ratios are near zero on reported figures, signalling a structural mismatch between balance-sheet bookkeeping and market pricing.
Pipeline, clinical risks, and news drivers
Neovacs develops therapeutic vaccines (IFNa Kinoid for lupus in Phase IIb and other programs). The last formal earnings announcement in the data set is dated 2019-10-02, so lack of recent corporate news likely amplified today’s selling.
Clinical milestones, regulatory updates, or financing notices will be the main catalysts. Absent clear trial or cash-flow news, the stock remains highly sensitive to any company statement.
Technical picture, liquidity and trading risk for ALNEV.PA stock
The technical indicators show oversold momentum: RSI 27.61 and ADX 29.67, with a sharp trend reading. Average 50-day price is €0.01648 and 200-day average is €3.66495, reflecting large historical swings and very low recent prices.
Relative liquidity is poor at low prices — bid/ask spreads and order book depth can magnify moves. Short-term traders face high volatility and limited ability to exit positions at predictable prices.
Meyka AI stock grade and model forecast for ALNEV.PA stock
Meyka AI rates ALNEV.PA with a score out of 100: 58.20 / 100 — Grade C+ (HOLD). This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are informational and not financial advice.
Meyka AI’s forecast model projects a cautious 12‑month baseline target of €0.0100, implying an upside of about +38.89% from €0.0072. Forecasts are model-based projections and not guarantees. Given cash and clinical uncertainties, downside scenarios remain material.
Risks, catalysts and what investors should monitor
Primary risks include continued thin float, absence of recent earnings updates, trial setbacks, and the need for fresh financing. The company’s small employee base (22 full-time) and limited market cap raise execution risk.
Key catalysts to watch are any corporate press release on clinical trial progress, a financing or strategic partner announcement, and clarified regulatory timelines. Each could swing price materially.
Final Thoughts
ALNEV.PA stock finished the session on 14 Jan 2026 at €0.0072, down 99.60%, with volume of 4,152,238 showing concentrated selling. The decline appears stock-specific and tied to company-level uncertainty: no recent earnings cadence since 2019, heavy clinical and financing risk, and minimal free-float liquidity. Our Meyka AI grade is 58.20 (C+, HOLD) and highlights mixed balance-sheet metrics against high operational risk. Meyka AI’s forecast model projects a €0.0100 12‑month target (implied upside +38.89% versus today). This projection assumes a baseline positive development or liquidity event; alternate scenarios could produce near-total capital loss. Investors should prioritise confirmed company disclosures, cash runway updates, and trial milestones before increasing exposure. Meyka AI provides this as an AI-powered market analysis platform insight; forecasts are model outputs and not guarantees.
FAQs
What caused the ALNEV.PA stock drop today?
The sharp drop to €0.0072 reflects stock-specific selling, thin liquidity, absence of recent earnings updates and high clinical and financing uncertainty rather than sector-wide news.
What is Meyka AI’s grade for ALNEV.PA stock and what does it mean?
Meyka AI rates ALNEV.PA 58.20/100 (C+, HOLD). The grade considers sector and benchmark comparison, financial growth, metrics and analyst signals. It is informational and not investment advice.
What price target and outlook does Meyka AI give for ALNEV.PA stock?
Meyka AI’s forecast model projects a €0.0100 12‑month baseline target from €0.0072 today, an implied upside of about +38.89%. Forecasts are model-based projections and not guarantees.
Which catalysts should investors watch for ALNEV.PA stock?
Monitor corporate press releases on clinical trials, financing or partnerships, cash-runway updates and any regulatory news. These events are the most likely to move the stock price materially.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
